Exchange: NASDAQ·Updated 09:01 AM EDT
ABEO logo

ABEO Abeona Therapeutics Inc

$6.02
$0.07
(1.18%)
Pre-Market
Prev Close $5.95
Reported EarningsAug 13
Mkt Cap$340.24M
Vol10,068.00

About ABEO

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
30

Bearish Sentiment

How do you feel about ABEO?

Advertisement|Remove ads.